Capri Holdings Ltd vs Johnson & Johnson — how do they compare? Capri Holdings Ltd trades at $15.62 (market cap $1.75B), while Johnson & Johnson trades at $260.7 (market cap $626.09B). The key difference: Johnson & Johnson is far larger — about 357.8× Capri Holdings Ltd's market cap, and Johnson & Johnson pays a 2.06% dividend while Capri Holdings Ltd pays none. Which is the better fit depends on your goals.
| CPRI | JNJ | |
|---|---|---|
Market Cap | $1.75B | $626.09B |
Sector | Consumer Staples | Health |
52-Week High | $27.66 | $267.24 |
52-Week Low | $14.98 | $172.78 |
Enterprise Value | $3.03B | $654.37B |
Volume | — | 6,156,228 |
Dividend Yield | — | 2.06% |
Signals from Pluang's Aura AI — not financial advice
Capri Holdings (CPRI) trades at $15.66, down 65% over five years and near 52-week lows after recent analyst downgrades. The stock shows bearish technical signals with neutral oscillators but faces fundamental challenges including declining revenue from $5.7B in 2022 to $4.4B in 2025 and a net loss of $1.18B last year. Recent Q1 2027 earnings beat expectations with $0.67 EPS versus $0.41 expected, driven by margin improvements and Jimmy Choo growth, though management cut full-year revenue guidance citing Michael Kors weakness.
The investment case hinges on successful execution of the post-Versace turnaround strategy, with the stock trading below consensus price targets offering potential upside if Michael Kors stabilizes. However, significant risks remain including ongoing revenue declines, luxury market softness, and high debt levels requiring careful monitoring of quarterly execution against revised guidance.
Johnson & Johnson (JNJ) trades at $260.88, down 0.36% today, with a bullish technical signal supported by moving averages. The stock shows strong profitability with a net margin of 21.48% and ROE of 25.74%, though valuations like a P/E of 30.14 appear elevated. Recent earnings beat expectations in Q1 and Q2 2026, and the company maintains a 64-year dividend growth streak, with analyst consensus leaning bullish.
Outlook remains positive with a consensus price target of $284.50, offering potential upside, but risks include legal challenges and high debt-to-asset ratio of 24.06% in 2025. Investors benefit from steady dividends and defensive positioning in healthcare, though valuation multiples may limit near-term gains amid economic uncertainty.
Trailing returns across standard periods
Latest headlines on both assets
Michael Kors, Versace, and Jimmy Choo are the brands of Capri Holdings, a marketer, distributor, and retailer of upscale accessories and apparel. Kors, Capri's largest brand, offers handbags, footwear, and apparel through more than 800 company-owned stores, wholesale, and e-commerce. Versace (acquired in 2018) is known for its ready-to-wear luxury fashion, while Jimmy Choo (acquired in 2017) is best known for women's luxury footwear. John Idol has served as CEO since 2003.
Read more on CPRI →Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →